Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?

Show other versions (1)

Background Bone mineral density (BMD) is influenced by multiple factors. Recent studies have highlighted a possible relationship between serotonin and BMD. Patients with neuroendocrine tumours (NETs) frequently have elevated urinary 5-hydroxy-indoleacetic acid (5-HIAA) levels, a serotonin metabolite...

Full description

Bibliographic Details
Main Authors:	Gupta, P, Grozinsky-Glasberg, S, Drake, WM, Akker, SA, Perry, L, Grossman, AB, Druce, MR
Format:	Journal article
Language:	English
Published:	2014

Similar Items

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
by: Sen Gupta, P, et al.
Published: (2014)

Evaluation of the Association between Serotonin and Bone Mineral Density in Patients with Neuroendocrine Tumors
by: Den Gupta, P, et al.
Published: (2011)

The role of somatostatin analogues in the treatment of neuroendocrine tumours.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

Intra-abdominal fibrosis in a recent cohort of patients with neuroendocrine ('carcinoid') tumours of the small bowel.
by: Druce, MR, et al.
Published: (2010)

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

Targeted radionuclide therapy for neuroendocrine tumours: principles and application.
by: Druce, MR, et al.
Published: (2010)

Intra-abdominal fibrosis in a modern cohort of patients with mid-gut carcinoid tumours - a cross-sectional survey from one centre
by: Druce, MR, et al.
Published: (2009)

Morbidity in patients on long-term steroid replacement therapy.
by: Druce, MR, et al.
Published: (2010)

Intracardiac metastases from neuroendocrine tumours.
by: Drake, WM, et al.
Published: (1997)

Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma
by: Druce, M, et al.
Published: (2012)

Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma.
by: Druce, M, et al.
Published: (2012)

Serotonin-Secreting Neuroendocrine Tumours of the Pancreas
by: Anna Caterina Milanetto, et al.
Published: (2020-05-01)

Update on neuroendocrine tumours
by: Grossman, AB
Published: (2012)

Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
by: Inbal Uri, et al.
Published: (2018-07-01)

Intra-Abdominal Fibrosis in a Modern Cohort of Patients with Mid-Gut Carcinoid Tumors - A Cross-Sectional Survey from One Centre
by: Druce, MR, et al.
Published: (2009)

Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms.
by: Kaltsas, G, et al.
Published: (2014)

MRI of pancreatic neuroendocrine tumours.
by: Owen, N, et al.
Published: (2001)

Preliminary Report of the Use of Everolimus in a Patient with Progressive Medullary Thyroid Carcinoma
by: Druce, M, et al.
Published: (2010)

Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours.
by: Chung, T, et al.
Published: (2008)

The effect of exogenous glucocorticoids on plasma catecholamines and metanephrines in patients without phaeochromocytomas.
by: Druce, MR, et al.
Published: (2011)

The Effect of Exogenous Glucocorticoids on Plasma Catecholamines and Metanephrines in Patients Without Phaeochromocytomas
by: Druce, MR, et al.
Published: (2012)

The Global mTOR Inhibitor Torin1 Is More Effective than the mTORC1 Inhibitor, Everolimus, Alone or in Combination with Histone Deacetylase Inhibitors, in Suppressing Neuroendocrine Tumor Cell Proliferation
by: Grozinsky-Glasberg, S, et al.
Published: (2011)

Paraneoplastic syndromes secondary to neuroendocrine tumours.
by: Kaltsas, G, et al.
Published: (2010)

Sequelae and survivorship in patients treated with 131 I-MIBG therapy
by: Sze, W, et al.
Published: (2013)

Sequelae and survivorship in patients treated with (131)I-MIBG therapy.
by: Sze, W, et al.
Published: (2013)

The role of chemotherapy management of malignant in the nonsurgical neuroendocrine tumours
by: Kaltsas, G, et al.
Published: (2001)

Preclinical drug studies in MEN1-related neuroendocrine neoplasms (MEN1-NENs)
by: Grozinsky-Glasberg, S, et al.
Published: (2020)

Plasma serotonin precursors and metabolite are correlated with bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis
by: Qinying Feng, et al.
Published: (2024-04-01)

Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review.
by: Dworakowska, D, et al.
Published: (2009)

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
by: Kaltsas, G, et al.
Published: (2005)

The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours.
by: Kaltsas, G, et al.
Published: (2001)

The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours.
by: Kaltsas, G, et al.
Published: (2001)

Neuroendocrine tumours: a hope and a prayer.
by: Grossman, A
Published: (2009)

Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours.
by: Kaltsas, G, et al.
Published: (2004)

Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors
by: Lines, K, et al.
Published: (2017)

Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours
by: Pedro Marques, et al.
Published: (2019-11-01)

Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement.
by: Chung, T, et al.
Published: (2005)

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

Gastroenteropancreatic neuroendocrine tumours.
by: Modlin, I, et al.
Published: (2008)

Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
by: Kaltsas, G, et al.
Published: (2002)